Clinical Trial Update: Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer [Phase 2]

View source ↗

Summary

Phase II trial of Sorafenib (Nexavar) in advanced thyroid cancers completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Thyroid Cancer
• Differentiated Thyroid Cancer
• Medullary Thyroid Cancer
• Poorly Differentiated Thyroid Cancer

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: University of Pennsylvania | Conditions: Metastatic Differentiated Thyroid Cancer, Metastatic Poorly Differentiated Thyroid Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-11-18